Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy
| Autor: | Isabelle Roque, Corinne Bodenant, Pierre Michel, Thierry Frebourg, Anne Chiron, Bernard Paillot, Valérie Robert, Karine Magois, Sok H Seng, Florence Lepessot |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male Transcriptional Activation Oncology Cancer Research medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Cell Population Proto-Oncogene Proteins p21(ras) Blood serum Proto-Oncogene Proteins Internal medicine Antineoplastic Combined Chemotherapy Protocols Immunochemistry Confidence Intervals medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Esophagus education neoplasms Aged bcl-2-Associated X Protein Chemotherapy education.field_of_study Ploidies Radiation business.industry Middle Aged Prognosis digestive system diseases Survival Rate Radiation therapy medicine.anatomical_structure Proto-Oncogene Proteins c-bcl-2 Mutation Carcinoma Squamous Cell Immunohistochemistry Female Fluorouracil Cisplatin Tumor Suppressor Protein p53 business |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 54:379-385 |
| ISSN: | 0360-3016 |
| Popis: | The aim of this study was to evaluate biologic factors on survival and clinical response after definitive concomitant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC).TP53 protein hyperexpression (immunochemistry [IHC]) and functional assay (FA) of TP53, measuring the ability of TP53 to transactivate p21 and bax reporter systems, were performed in patients with ESCC treated by CRT. The impact of parameters studied on survival and clinical response to CRT was assessed.Thirty-eight patients with ESCC were included. TP53 alterations were detected in 84.2% of cases with FA. All TP53 mutations abolished the transactivation of p21 and bax reporter systems. After CRT, complete response rate was 55.3%. The median survival of the population was 17.5 months. Serum albumin (p = 0.002), weight loss10% (p = 0.005), and response to treatment (p0.001) were significantly linked with survival. TP53 alteration in FA was not significantly predictive of response to CRT (p = 0.132) nor survival (p = 0.154).Our results suggest that wild-type TP53 in ESCC could be associated with good response to definitive CRT. However, the small rate of ESCC with wild-type TP53 suggests that systematic determination of TP53 status is not appropriate for the management of the ESCC population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|